Corporate & PKU Overview February 2016 Corporate History 2017 UCD & PKU Programs: Ph1b Data [ YE2016/1H2017 ] IND Filing 2016 December 2015: July 2015: $40M Series B round TS signed IBD collaboration signed with AbbVie 2015 November 2014: Start of lab operations July/October 2014: $29.4M Series A round: Atlas Ventures, NEA, and B&M Gates Foundation) 2014 Scientific Co-Founders: Dr. James Collins & Dr. March 2013: Timothy Lu Synlogic Incorporated (fkaTMC Therapeutics; seeded at Atlas Venture) 2013 2 2 S B : Precision Programmed Probiotics YNTHETIC IOTICS to Treat Serious Diseases Synthetic Biotics Selective and predictable pharmacology Precision Programming Designed to be safe Oral administration Designed to perform metabolic functions in the gut to treat diseases 400+ $3.5 B species of sales probiotic probiotics in supplements & our body products, U.S.* (2015) *Statista 2016 3 Synthetic Biotics: A New Class of Drugs Synthetic Biotics • Engineered bacteria • Probiotic bacteria: E. coli Nissle • Genetic circuits that perform • Derived from natural human metabolic transformations microbiome • Designed synthetically to degrade • Extensive safety in humans as metabolites that induce disease probiotic or synthesize substances that • Daily, oral administration can treat disease Synthetic Biotics Therapeutic action from the microbiome to correct metabolic dysregulation throughout the body 4 Synthetic Biotics: Therapeutics that Operate from our Natural Microbiome Synlogic's synthetic biotics are oral bacterial drug products that blend with the patient microbiome where they perform their programmed therapeutic metabolic transformations … …. to correct metabolite dysregulation that is causing chronic disease throughout the body 5 Synlogic is at the Convergence of Two Revolutionary Fields in Life Sciences 2 Revolutionary Fields Synthetic Biology Microbiome Probiotic Synthetic Biotics • Transformative therapies • Pipeline of products • Value Creation in compressed timeline Rare Major Diseases Diseases Therapeutic Drug Products 6 Synlogic’s Drug Discovery and Development Approach Inborn Errors of ✓ Metabolism Genetic circuits Synthetic specialized in Biotic metabolic transformations Correct the deficiency Probiotic bacteria: E. coli Nissle 7 A Simple, Robust and Rapid Platform for Generating Synthetic Biotics DEFINE DISEASE PATHWAY DESIGN ASSIMILATE CIRCUIT IN THE MICROBIOME BUILD SYNTHETIC BIOTIC • Metabolic pathway • Genetic circuits • Bacterial engineering • System check expertise • Switches • “Chassis” optimization • GI dynamics • Drug development • Bacterial technologies • Bacterial genome • Potency in vitro and in experience • Enzyme selection integration landing vivo • Understanding of pads • Blend into microbiome • Genomic integration disease processes technologies • Stable integration without colonization • Differentiated TPP 8 Synlogic’s Initial Focus: Inborn Errors of Metabolism Disease Toxic Metabolite Urea Cycle Disorders Ammonia Phenylketonuria Phenylalanine Organic Acidemias Propionate Maple Syrup Urine Ile, Leu, Val Disease Homocysteine, Homocysteinuria Methionine Xanthinuria Type 1 Xanthine Primary Hyperoxaluria Oxalate 9 Synthetic Biotics Can Mediate Broad-Range of Metabolite Transformations in the Gut Phenylketonuria AMINO ACID METABOLISM (PKU) Phenylalanine Oncology Leucine Aging Maple Syrup Isoleucine Urinary disease Valine (MSUD) Enabling SHORT AND MEDIUM CHAIN for broader FATTY ACID METABOLISM pathway Organic applications Propionate Inflammation Acidemias in the gut Butyrate Autoimmune & Metabolic Disease TOXIC METABOLITE CONVERSION Urea Cycle Ammonia Liver Disease Disorders Chronic Kidney Disease Oncology Detoxification 10